{"protocolSection": {"identificationModule": {"nctId": "NCT00156819", "orgStudyIdInfo": {"id": "ALAACRC-03"}, "organization": {"fullName": "JHSPH Center for Clinical Trials", "class": "OTHER"}, "briefTitle": "The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial", "officialTitle": "The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial"}, "statusModule": {"statusVerifiedDate": "2015-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2003-06"}, "primaryCompletionDateStruct": {"date": "2005-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2006-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-08", "studyFirstSubmitQcDate": "2005-09-08", "studyFirstPostDateStruct": {"date": "2005-09-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-11-04", "resultsFirstSubmitQcDate": "2015-11-04", "resultsFirstPostDateStruct": {"date": "2015-12-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-11-04", "lastUpdatePostDateStruct": {"date": "2015-12-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"leadSponsor": {"name": "JHSPH Center for Clinical Trials", "class": "OTHER"}, "collaborators": [{"name": "GlaxoSmithKline", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "This research study will compare the treatment effects of three different asthma medications in asthma subjects whose asthma is well controlled when they take fluticasone, an inhaled corticosteroid. The treatments are fluticasone, montelukast (an anti?leukotriene drug), and a combination therapy of fluticasone and salmeterol (a long-acting beta-agonist). Fluticasone, montelukast, and the combination therapy of fluticasone and salmeterol (Advair Diskus\u00ae) are all approved for the treatment of asthma. We are looking at whether the three treatments are equally effective for reducing the number and the severity of asthma attacks in subjects with mild to moderately severe asthma.", "detailedDescription": "This trial will attempt to investigate whether asthmatic patients that are well controlled with low-dose twice daily inhaled corticosteroid (ICS) therapy can safely be switched to other modes of controller therapy without loss of asthma control. Patients demonstrating good control on twice-daily low-dose ICS will be randomized to one of three treatment groups: once-daily low-dose ICS (fluticasone), leukotriene receptor antagonist (montelukast), or once-daily combination therapy (fluticasone-salmeterol)."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Asthma Control"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 500, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fluticasone", "type": "ACTIVE_COMPARATOR", "description": "Participants continued fluticasone (100 microgram twice daily) treatment.", "interventionNames": ["Drug: fluticasone", "Drug: montelukast", "Drug: Fluticasone plus salmeterol"]}, {"label": "Montelukast", "type": "EXPERIMENTAL", "description": "Participants were changed to Montelukast (5 or 10 mg each night).", "interventionNames": ["Drug: fluticasone", "Drug: montelukast", "Drug: Fluticasone plus salmeterol"]}, {"label": "Fluticasone plus salmeterol", "type": "EXPERIMENTAL", "description": "Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.", "interventionNames": ["Drug: fluticasone", "Drug: montelukast", "Drug: Fluticasone plus salmeterol"]}], "interventions": [{"type": "DRUG", "name": "fluticasone", "description": "fluticasone (100 microgram twice daily) treatment", "armGroupLabels": ["Fluticasone", "Fluticasone plus salmeterol", "Montelukast"]}, {"type": "DRUG", "name": "montelukast", "description": "Montelukast (5 or 10 mg each night).", "armGroupLabels": ["Fluticasone", "Fluticasone plus salmeterol", "Montelukast"]}, {"type": "DRUG", "name": "Fluticasone plus salmeterol", "description": "fluticasone (100 microgram) plus salmeterol (50 microgram) each night", "armGroupLabels": ["Fluticasone", "Fluticasone plus salmeterol", "Montelukast"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Treatment Failure", "description": "The primary outcome measure was treatment failure, defined as the occurrence of any one of the following events: hospitalization or an urgent medical visit for asthma initiated by the patient or physician; use of systemic corticosteroids for asthma or need for open-label use of inhaled corticosteroids for asthma, as determined by the study physician or an asthma care provider; a decrease in prebronchodilator forced expiratory volume in 1 second (FEV1) to more than 20% below the baseline value measured at randomization; a decrease in the morning peak expiratory flow rate to more than 35% below the baseline value (the mean over the final 2 weeks of the run-in period) on 2 consecutive days; use of 10 puffs or more per day of rescue beta-agonist for 2 consecutive days (except as medication before exercise); refusal of the patient to continue because of lack of satisfaction with treatment; or judgment by a physician that the patient should stop treatment for reasons of safety.", "timeFrame": "16 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* physician-diagnosed asthma\n* age 6 or older\n* pre-bronchodilator forced expiratory volume (FEV1) of at least 60% of predicted\n* beta-agonist reversibility OR airways hyperreactivity by methacholine challenge\n* Juniper Asthma Control Score of 1.5 or greater if not on daily controller\n* good current health\n\nExclusion Criteria:\n\n* current or past smoking (greater than 20 pack-years)\n* chronic or current oral steroid therapy\n* pregnancy, lack of effective contraception (when appropriate), lactation", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Nicholas Anthonisen, MD", "affiliation": "University of Winnipeg", "role": "STUDY_CHAIR"}], "locations": [{"facility": "University of Alabama at Birmingham", "city": "Birmingham", "state": "Alabama", "zip": "35233", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "National Jewish Hospital", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Nemour's Childrens Center", "city": "Jacksonville", "state": "Florida", "zip": "32207", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "University of Miami (and University of South Florida in Tampa)", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Illinois Consortium (Northwestern, Univ. of Chicago, Univ. of Illinois)", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Indiana University", "city": "Indianapolis", "state": "Indiana", "zip": "46202", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Louisiana State University", "city": "New Orleans", "state": "Louisiana", "zip": "70112", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"facility": "University of Minnesota", "city": "Minneapolis", "state": "Minnesota", "zip": "55455", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "University of Missouri at Kansas City", "city": "Kansas City", "state": "Missouri", "zip": "64108", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Washington University", "city": "St. Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Long Island Jewish Hospital (and North Shore Hospital)", "city": "New Hyde Park", "state": "New York", "zip": "11040", "country": "United States", "geoPoint": {"lat": 40.7351, "lon": -73.68791}}, {"facility": "New York Consortium (New York Univ. and Columbia Univ.)", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "New York Medical College", "city": "Valhalla", "state": "New York", "zip": "10595", "country": "United States", "geoPoint": {"lat": 41.07482, "lon": -73.77513}}, {"facility": "Duke University School of Medicine", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Ohio State University", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Thomas Jefferson Hospital", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Baylor College of Medicine", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Northern New England Consortium (Univ. of Vermont and other locations)", "city": "Burlington", "state": "Vermont", "zip": "05405", "country": "United States", "geoPoint": {"lat": 44.47588, "lon": -73.21207}}]}, "referencesModule": {"references": [{"pmid": "21799027", "type": "DERIVED", "citation": "Lang JE, Hossain J, Dixon AE, Shade D, Wise RA, Peters SP, Lima JJ; American Lung Association-Asthma Clinical Research Centers. Does age impact the obese asthma phenotype? Longitudinal asthma control, airway function, and airflow perception among mild persistent asthmatics. Chest. 2011 Dec;140(6):1524-1533. doi: 10.1378/chest.11-0675. Epub 2011 Jul 28."}, {"pmid": "20851928", "type": "DERIVED", "citation": "Duan QL, Gaume BR, Hawkins GA, Himes BE, Bleecker ER, Klanderman B, Irvin CG, Peters SP, Meyers DA, Hanrahan JP, Lima JJ, Litonjua AA, Tantisira KG, Liggett SB. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med. 2011 Feb 15;183(4):449-54. doi: 10.1164/rccm.201005-0758OC. Epub 2010 Sep 17."}, {"pmid": "17507702", "type": "DERIVED", "citation": "American Lung Association Asthma Clinical Research Centers; Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, Wise RA. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med. 2007 May 17;356(20):2027-39. doi: 10.1056/NEJMoa070013. Erratum In: N Engl J Med. 2007 Aug 16;357(7):728."}], "seeAlsoLinks": [{"label": "American Lung Association Asthma Clinical Research Centers", "url": "http://www.cctrials.org/alaacrc"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Fluticasone", "description": "Participants continued fluticasone (100 microgram twice daily) treatment.\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night"}, {"id": "FG001", "title": "Montelukast", "description": "Participants were changed to Montelukast (5 or 10 mg each night).\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night"}, {"id": "FG002", "title": "Fluticasone Plus Salmeterol", "description": "Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "169"}, {"groupId": "FG001", "numSubjects": "166"}, {"groupId": "FG002", "numSubjects": "165"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "168"}, {"groupId": "FG001", "numSubjects": "165"}, {"groupId": "FG002", "numSubjects": "162"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Fluticasone", "description": "Participants continued fluticasone (100 microgram twice daily) treatment.\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night"}, {"id": "BG001", "title": "Montelukast", "description": "Participants were changed to Montelukast (5 or 10 mg each night).\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night"}, {"id": "BG002", "title": "Fluticasone Plus Salmeterol", "description": "Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "169"}, {"groupId": "BG001", "value": "166"}, {"groupId": "BG002", "value": "165"}, {"groupId": "BG003", "value": "500"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.3", "spread": "14.6"}, {"groupId": "BG001", "value": "32.4", "spread": "15.4"}, {"groupId": "BG002", "value": "30.8", "spread": "14.9"}, {"groupId": "BG003", "value": "30.8", "spread": "15.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "103"}, {"groupId": "BG001", "value": "95"}, {"groupId": "BG002", "value": "103"}, {"groupId": "BG003", "value": "301"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "66"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "62"}, {"groupId": "BG003", "value": "199"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Treatment Failure", "description": "The primary outcome measure was treatment failure, defined as the occurrence of any one of the following events: hospitalization or an urgent medical visit for asthma initiated by the patient or physician; use of systemic corticosteroids for asthma or need for open-label use of inhaled corticosteroids for asthma, as determined by the study physician or an asthma care provider; a decrease in prebronchodilator forced expiratory volume in 1 second (FEV1) to more than 20% below the baseline value measured at randomization; a decrease in the morning peak expiratory flow rate to more than 35% below the baseline value (the mean over the final 2 weeks of the run-in period) on 2 consecutive days; use of 10 puffs or more per day of rescue beta-agonist for 2 consecutive days (except as medication before exercise); refusal of the patient to continue because of lack of satisfaction with treatment; or judgment by a physician that the patient should stop treatment for reasons of safety.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "16 weeks", "groups": [{"id": "OG000", "title": "Fluticasone", "description": "Participants continued fluticasone (100 microgram twice daily) treatment.\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night"}, {"id": "OG001", "title": "Montelukast", "description": "Participants were changed to Montelukast (5 or 10 mg each night).\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night"}, {"id": "OG002", "title": "Fluticasone Plus Salmeterol", "description": "Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "165"}, {"groupId": "OG002", "value": "162"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "33"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Fluticasone", "description": "Participants continued fluticasone (100 microgram twice daily) treatment.\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night", "seriousNumAffected": 6, "seriousNumAtRisk": 168, "otherNumAffected": 159, "otherNumAtRisk": 168}, {"id": "EG001", "title": "Montelukast", "description": "Participants were changed to Montelukast (5 or 10 mg each night).\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night", "seriousNumAffected": 4, "seriousNumAtRisk": 165, "otherNumAffected": 156, "otherNumAtRisk": 165}, {"id": "EG002", "title": "Fluticasone Plus Salmeterol", "description": "Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.\n\nfluticasone: fluticasone (100 microgram twice daily) treatment\n\nmontelukast: Montelukast (5 or 10 mg each night).\n\nFluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night", "seriousNumAffected": 4, "seriousNumAtRisk": 162, "otherNumAffected": 157, "otherNumAtRisk": 162}], "seriousEvents": [{"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Suffered concussion while snowboarding.", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 162}]}, {"term": "Chest pain", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 162}]}, {"term": "Partial right knee replacement surgery", "organSystem": "Surgical and medical procedures", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 162}]}, {"term": "Drop in peak flow", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 162}]}, {"term": "Anaphylactic reaction to peanuts", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 162}]}, {"term": "Asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 162}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 162}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 162}]}, {"term": "Allergic reaction to Bactim", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 162}]}, {"term": "Elbow sprain", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 162}]}, {"term": "Abcess", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 162}]}, {"term": "Tonsilectomy", "organSystem": "Surgical and medical procedures", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 162}]}], "otherEvents": [{"term": "Upper respiratory infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 63, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 44, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 62, "numAtRisk": 162}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 83, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 82, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 78, "numAtRisk": 162}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 120, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 111, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 118, "numAtRisk": 162}]}, {"term": "Upper respiratory inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 84, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 67, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 73, "numAtRisk": 162}]}, {"term": "Hoarsness/ dysphonia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 92, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 78, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 87, "numAtRisk": 162}]}, {"term": "Sinisitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 67, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 51, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 50, "numAtRisk": 162}]}, {"term": "Nasal congestion", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 136, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 127, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 129, "numAtRisk": 162}]}, {"term": "Viral respiratory infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 22, "numAtRisk": 162}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 162}]}, {"term": "Headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 120, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 117, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 112, "numAtRisk": 162}]}, {"term": "Diarrhea", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 41, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 31, "numAtRisk": 162}]}, {"term": "Nausea and vomitting", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 55, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 37, "numAtRisk": 162}]}, {"term": "Gastrointestinal distress", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 63, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 57, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 61, "numAtRisk": 162}]}, {"term": "Fever", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 45, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 25, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 36, "numAtRisk": 162}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 63, "numAtRisk": 168}, {"groupId": "EG001", "numAffected": 71, "numAtRisk": 165}, {"groupId": "EG002", "numAffected": 70, "numAtRisk": 162}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Razan Yasin", "organization": "Johns Hopkins Center for Clinical Trials", "email": "ryasin1@jhu.edu", "phone": "443-287-5796"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}